Speakers from Touchstone Exploration, Shanta Gold, Savannah Resources and Kavango Resources feature in our Natural Resources webinar on May 25th. Please register here.

Less Ads, More Data, More Tools Register for FREE

WRAPUP 2-AstraZeneca resumes U.S. COVID-19 vaccine trial, optimism seen for J&J

Fri, 23rd Oct 2020 20:54

(Adds background details)

Oct 23 (Reuters) - AstraZeneca Plc has resumed the
U.S. trial of its experimental COVID-19 vaccine after approval
by U.S. regulators, the company said on Friday.

AstraZeneca's U.S. trial was paused on Sept. 6 after a
report of a serious neurological illness, believed to be
transverse myelitis, in a participant in the company's UK trial.

U.S. Health and Human Services Deputy Chief of Staff Paul
Mango also told reporters he was optimistic a U.S. trial by
Johnson & Johnson would resume.

J&J paused its large, late-stage trial last week after a
study participant became ill and the company said an independent
safety panel was investigating.

AstraZeneca trials in the United Kingdom, Brazil and South
Africa resumed last month even as the U.S. Food and Drug
Administration continued its investigation into the case.

Reuters earlier this week reported that the FDA had
completed its review and that the AstraZeneca U.S. trial was set
to resume as early as this week, citing four sources familiar
with the situation.

AstraZeneca's vaccine is being developed along with
researchers at Oxford University.
(Reporting by Munsif Vengattil and Carl O'Donnell; Editing by
Anil D'Silva, Rosalba O'Brien and Grant McCool)

Related Shares

More News

Tuesday broker round-up

(Sharecast News) - BP: Barclays upgrades to top pick with a target price of 475p.

18 May 21 14:00

Oxford Biomedica jumps after AstraZeneca orders more Covid-19 vaccines

Oxford Biomedica jumps after AstraZeneca orders more Covid-19 vaccines

18 May 21 11:52

Oxford Biomedica ups revenue forecast as AstraZeneca lifts vaccine output

(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Tuesday doubled annual earnings guidance after pharmaceutical giant AstraZeneca ordered more Covid-19 vaccines.

18 May 21 08:13

LONDON MARKET PRE-OPEN: Phoenix Group confirms talks for European sale

LONDON MARKET PRE-OPEN: Phoenix Group confirms talks for European sale

18 May 21 07:47

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.